Halozyme Therapeutics Inc., of San Diego, and Genentech, a member of the Roche Group, of Basel, Switzerland, said they will collaborate on clinical studies evaluating up to eight different tumor types beginning next year. The first study will be a phase Ib/II open-label, multi-arm, randomized, global study, led by Genentech to evaluate its cancer immunotherapy, Tecentriq (atezolizumab), an anti-PD-L1 monoclonal antibody, in combination with Halozyme's investigational drug, PEGPH20, in six tumor types. Halozyme will supply its drug only for the Genentech study.